EU Approves Sanofi’s (SNY) Sarclisa for Newly Diagnosed Multiple Myeloma Patients

Sanofi (NASDAQ:SNY) ranks among the best medical stocks to buy according to analysts. On July 25, Sanofi (NASDAQ:SNY) announced that Sarclisa, one of its medications, has been approved by the European Union for the treatment of newly diagnosed multiple myeloma patients who are eligible for transplantation. The approval significantly broadens the scope of treatment for Sarclisa by extending its use across all therapeutic lines in the EU.

EU Approves Sanofi’s (SNY) Sarclisa for Newly Diagnosed Multiple Myeloma Patients

The French pharmaceutical company claims that Sarclisa-VRD showed great improvement in the minimum residual disease (MRD) negativity, a crucial indicator of how well a treatment is working for patients with multiple myeloma.

With this regulatory milestone, Sarclisa’s approvals have been expanded to include multiple myeloma patients at different phases of their treatment cycle within the European Union.

Sanofi (NASDAQ:SNY) is a leading French healthcare company. Its primary goal is to enhance patient health through research, development, production, and promotion of a variety of therapeutic options.

While we acknowledge the potential of SNY to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than SNY and that has 100x upside potential, check out our report about this cheapest AI stock.

Read More: 10 Best Magic Formula Stocks for 2025 and 10 Best Retirement Stocks to Buy According to Hedge Funds

Disclosure: None.